Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca has told investors that its marketed products such as Crestor and Seroquel could continue to drive profits while the company rebuilds its product pipeline.
Subscribe to our email newsletter
The company’s chief executive David Brennan said that the company plans to strengthen its pipeline, weakened by a string of product failures, through improving the productivity of its in-house drug discovery and development whilst continuing to acquire promising technologies from other companies.
Mr Brennan also referred to the recent GBP702 million bid for the biotechnology company Cambridge Antibody Technology, and suggested that there may be more deals of a similar nature to follow with the company keen to build “a major international presence in the research and development of biological therapeutics to complement our small molecule capabilities.”
The company believes that effective life-cycle management of the antipsychotic Seroquel, the statin Crestor, and the asthma drug Symbicort would continue to drive top line growth.